Literature DB >> 34723855

New onset kidney impairment in a large pre-exposure prophylaxis demonstration project in New South Wales, Australia.

Gregory M Lucas1, Dean L Winslow2.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34723855      PMCID： PMC8982901          DOI： 10.1097/QAD.0000000000003077

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  22 in total

1.  Risk factors of chronic kidney disease in HIV-infected patients.

Authors:  Philippe Flandre; Pascal Pugliese; Lise Cuzin; Corinne Isnard Bagnis; Ivan Tack; André Cabié; Isabelle Poizot-Martin; Christine Katlama; Cécile Brunet-François; Yazdan Yazdanpanah; Pierre Dellamonica
Journal:  Clin J Am Soc Nephrol       Date:  2011-05-12       Impact factor: 8.237

2.  Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2).

Authors:  Yuichi Uwai; Hiroki Ida; Yoshie Tsuji; Toshiya Katsura; Ken-Ichi Inui
Journal:  Pharm Res       Date:  2007-02-15       Impact factor: 4.200

3.  Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.

Authors:  Gregory M Lucas; Michael J Ross; Peter G Stock; Michael G Shlipak; Christina M Wyatt; Samir K Gupta; Mohamed G Atta; Kara K Wools-Kaloustian; Paul A Pham; Leslie A Bruggeman; Jeffrey L Lennox; Patricio E Ray; Robert C Kalayjian
Journal:  Clin Infect Dis       Date:  2014-09-17       Impact factor: 9.079

4.  Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.

Authors:  Kenneth K Mugwanya; Christina Wyatt; Connie Celum; Deborah Donnell; Nelly R Mugo; Jordan Tappero; James Kiarie; Allan Ronald; Jared M Baeten
Journal:  JAMA Intern Med       Date:  2015-02       Impact factor: 21.873

5.  Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis.

Authors:  Rochelle P Walensky; Tim Horn; Nicole C McCann; Kenneth A Freedberg; A David Paltiel
Journal:  Ann Intern Med       Date:  2020-03-10       Impact factor: 25.391

6.  Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Onyema Ogbuagu; Peter J Ruane; Daniel Podzamczer; Laura C Salazar; Keith Henry; David M Asmuth; David Wohl; Richard Gilson; Yongwu Shao; Ramin Ebrahimi; Stephanie Cox; Alexander Kintu; Christoph Carter; Moupali Das; Jared M Baeten; Diana M Brainard; Gary Whitlock; Jason M Brunetta; Gitte Kronborg; Christoph D Spinner
Journal:  Lancet HIV       Date:  2021-07       Impact factor: 12.767

7.  The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.

Authors:  J J Kiser; M L Carten; C L Aquilante; P L Anderson; P Wolfe; T M King; T Delahunty; L R Bushman; C V Fletcher
Journal:  Clin Pharmacol Ther       Date:  2007-06-27       Impact factor: 6.875

8.  How safe is TDF/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP.

Authors:  Victoria Pilkington; Andrew Hill; Sophie Hughes; Nneka Nwokolo; Anton Pozniak
Journal:  J Virus Erad       Date:  2018-10-01

9.  Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis.

Authors:  Marc M Solomon; Javier R Lama; David V Glidden; Kathleen Mulligan; Vanessa McMahan; Albert Y Liu; Juan Vicente Guanira; Valdilea G Veloso; Kenneth H Mayer; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Esper Georges Kallás; David N Burns; Robert M Grant
Journal:  AIDS       Date:  2014-03-27       Impact factor: 4.177

10.  Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure.

Authors:  Sophie Jose; Lisa Hamzah; Lucy J Campbell; Teresa Hill; Martin Fisher; Clifford Leen; Richard Gilson; John Walsh; Mark Nelson; Phillip Hay; Margaret Johnson; David Chadwick; Dorothea Nitsch; Rachael Jones; Caroline A Sabin; Frank A Post
Journal:  J Infect Dis       Date:  2014-02-28       Impact factor: 5.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.